^
    1d
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Feb 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    1d
    Postoperative Hypocalcemia After Thyroidectomy (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Minia University | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience. (PubMed, Endocr Pathol)
    Co-occurring genetic alterations with RAS mutations markedly increased the risk of malignancy compared with isolated RAS mutations (Fisher's exact test, two-tailed p = 0.0026) and were associated with more aggressive tumor phenotypes, whereas isolated RAS mutations were more common in indolent neoplasms. Comprehensive molecular profiling is essential for accurate risk stratification and management of indeterminate thyroid nodules.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • RAS (Rat Sarcoma Virus) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation
    2d
    Solid Subtype of Papillary Thyroid Carcinoma: A Case Series Highlighting Aggressive Features. (PubMed, Clin Case Rep)
    STPTC can exhibit aggressive behavior, particularly in young patients. Early diagnosis and individualized therapeutic approaches are essential to improve clinical outcomes.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • KRT19 (Keratin 19) • TP63 (Tumor protein 63) • PAX8 (Paired box 8) • SYP (Synaptophysin)
    2d
    SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov)
    P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Mycapssa (octreotide) • Avzivi (bevacizumab-tnjn) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b) • octreotide acetate
    2d
    Can Desmoplastic Stromal Reaction Guide the Extent of Lymph Node Surgery in Sporadic Medullary Thyroid Carcinoma? (PubMed, World J Surg)
    DSR negativity reliably identifies an indolent subgroup with negligible metastatic risk, whereas increasing desmoplasia stratifies patients into higher-risk categories. The incorporation of DSR alongside established biomarkers such as Ctn may refine surgical decision-making and may help tailor the extent of LN dissection in sporadic MTC.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    2d
    Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET. (PubMed, ESMO Open)
    Selpercatinib conferred significant PFS benefit over SoC in treatment-naïve (1L) patients with RET-mutation-positive MTC, with inconclusive results in the ≥2L setting. Matching retrospective real-world data to prospective trial data is feasible. EC arms to single-arm trials may provide evidence supporting the evaluation of comparative effectiveness.
    Journal • Real-world evidence • IO biomarker
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
    2d
    Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3d
    Case Report: Membranous/cytoplasmic Ki-67 staining and PAX8-GLIS3 fusion: defining the clinicopathological spectrum of hyalinizing trabecular tumor to optimize patient management. (PubMed, Front Med (Lausanne))
    The use of Ki-67 immunohistochemistry or PAX8-GLIS3 testing on cytological specimens can aid in definitive diagnosis and prevent unnecessary surgery. Thus, an integrated approach combining cytological, histological, immunohistochemical, and molecular data is essential for the accurate diagnosis and optimal clinical management of HTT.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TTF1 (Transcription Termination Factor 1) • NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
    |
    BRAF mutation • PIK3CA mutation
    3d
    Postoperative Radiotherapy Combined With Nimotuzumab Followed by Bemcentinib in High-Risk Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    cisplatin • bemcentinib (BGB324) • TheraCIM (nimotuzumab)
    3d
    Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=12, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Feb 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • etoposide IV
    4d
    JPMS-DTC: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (clinicaltrials.gov)
    P=N/A, N=453, Active, not recruiting, Bayer | Trial completion date: Nov 2025 --> Sep 2026
    Trial completion date
    |
    sorafenib